{
  "DOI": "10.1007/s12687-020-00480-6",
  "ISSN": [
    "1868-310X",
    "1868-6001"
  ],
  "URL": "http://dx.doi.org/10.1007/s12687-020-00480-6",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eDiseases caused by alterations in the DNA can be overcome by providing the cells or tissues with a functional copy of the mutated gene. The most common form of gene therapy implies adding an extra genetic unit into the cell. However, new genome engineering techniques also allow the modification or correction of the existing allele, providing new possibilities, especially for dominant diseases. Gene therapies have been tested for 30 years in thousands of clinical trials, but presently, we have only three authorised gene therapy products for the treatment of inherited diseases in European Union. Here, we describe the gene therapy alternatives already on the market in the European Union and expand the scope to some clinical trials. Additionally, we discuss the ethical and regulatory issues raised by the development of these new kinds of therapies.\u003c/jats:p\u003e",
  "alternative-id": [
    "480"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "16 March 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "29 July 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "15 August 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Authors RM and SJ declare having no conflict of interest. Author KW has received a speaker honorarium from Novartis."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "This article does not contain any studies with human participants performed by any of the authors."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Maldonado",
      "given": "Rocio",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Jalil",
      "given": "Sami",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-5677-1117",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Wartiovaara",
      "given": "Kirmo",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Journal of Community Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        8,
        15
      ]
    ],
    "date-time": "2020-08-15T03:56:41Z",
    "timestamp": 1597463801000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        11,
        7
      ]
    ],
    "date-time": "2022-11-07T01:13:49Z",
    "timestamp": 1667783629000
  },
  "funder": [
    {
      "name": "University of Helsinki including Helsinki University Central Hospital"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        7
      ]
    ],
    "date-time": "2024-03-07T13:22:38Z",
    "timestamp": 1709817758274
  },
  "is-referenced-by-count": 12,
  "issn-type": [
    {
      "type": "print",
      "value": "1868-310X"
    },
    {
      "type": "electronic",
      "value": "1868-6001"
    }
  ],
  "issue": "2",
  "issued": {
    "date-parts": [
      [
        2020,
        8,
        15
      ]
    ]
  },
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2021,
          4
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            8,
            15
          ]
        ],
        "date-time": "2020-08-15T00:00:00Z",
        "timestamp": 1597449600000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            8,
            15
          ]
        ],
        "date-time": "2020-08-15T00:00:00Z",
        "timestamp": 1597449600000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s12687-020-00480-6.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s12687-020-00480-6/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s12687-020-00480-6.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "267-276",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2020,
        8,
        15
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        8,
        15
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2021,
        4
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1038/s41586-019-1711-4",
      "author": "AV Anzalone",
      "doi-asserted-by": "publisher",
      "first-page": "149",
      "journal-title": "Nature.",
      "key": "480_CR1",
      "unstructured": "Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, Newby GA, Raguram A, Liu DR (2019) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 576:149–157. https://doi.org/10.1038/s41586-019-1711-4",
      "volume": "576",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41591-019-0601-5",
      "doi-asserted-by": "crossref",
      "key": "480_CR2",
      "unstructured": "Bai T, Li J, Sinclair A, Imren S, Merriam F, Sun F, O’Kelly MB, Nourigat C, Jain P, Delrow JJ, Basom RS, Hung H-C, Zhang P, Li B, Heimfeld S, Jiang S, Delaney C (2019) Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel. Nat Med 25(10):1566–1575"
    },
    {
      "DOI": "10.1056/NEJMoa0802268",
      "author": "JWB Bainbridge",
      "doi-asserted-by": "publisher",
      "first-page": "2231",
      "journal-title": "N Engl J Med",
      "key": "480_CR3",
      "unstructured": "Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231–2239. https://doi.org/10.1056/NEJMoa0802268",
      "volume": "358",
      "year": "2008"
    },
    {
      "DOI": "10.2174/15665232113136660005",
      "author": "A Baldo",
      "doi-asserted-by": "publisher",
      "first-page": "385",
      "journal-title": "Curr Gene Ther",
      "key": "480_CR4",
      "unstructured": "Baldo A, den Akker E, Bergmans H, Lim F, Pauwels K (2014) General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Curr Gene Ther 13:385–394. https://doi.org/10.2174/15665232113136660005",
      "volume": "13",
      "year": "2014"
    },
    {
      "key": "480_CR5",
      "unstructured": "BIOTECH Gene Therapy (2016) https://twitter.com/_b_i_o_t_e_c_h_/status/774586084575551488. Accessed 17 February 2020"
    },
    {
      "DOI": "10.1038/mtna.2016.52",
      "doi-asserted-by": "crossref",
      "key": "480_CR6",
      "unstructured": "Bjurström CF, Mojadidi M, Phillips J, Kuo C, Lai S, Lill GR, Cooper A, Kaufman M, Urbinati F, Wang X, Hollis RP, Kohn DB (2016) Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases. Mol Ther - Nucleic Acids 5:e351"
    },
    {
      "DOI": "10.1126/science.270.5235.475",
      "author": "RM Blaese",
      "doi-asserted-by": "publisher",
      "first-page": "475",
      "journal-title": "Science.",
      "key": "480_CR7",
      "unstructured": "Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 270:475–480. https://doi.org/10.1126/science.270.5235.475",
      "volume": "270",
      "year": "1995"
    },
    {
      "DOI": "10.1182/blood-2012-09-455238",
      "author": "JJ Boelens",
      "doi-asserted-by": "publisher",
      "first-page": "3981",
      "journal-title": "Blood.",
      "key": "480_CR8",
      "unstructured": "Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, DeFor T, Wynn R et al (2013) Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 121:3981–3987. https://doi.org/10.1182/blood-2012-09-455238",
      "volume": "121",
      "year": "2013"
    },
    {
      "DOI": "10.1073/pnas.0807027105",
      "author": "AV Cideciyan",
      "doi-asserted-by": "publisher",
      "first-page": "15112",
      "journal-title": "Proc Natl Acad Sci U S A",
      "key": "480_CR9",
      "unstructured": "Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EAM, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 105:15112–15117. https://doi.org/10.1073/pnas.0807027105",
      "volume": "105",
      "year": "2008"
    },
    {
      "key": "480_CR10",
      "unstructured": "Clinical trials NIH (2020) https://clinicaltrials.gov/. Accessed February 2020"
    },
    {
      "key": "480_CR11",
      "unstructured": "Council of Europe (1997) Convention for the protection of human rights and dignity of the human being with regard to the application of Biology and Medicine: convention on human rights and biomedicine. Council of Europe. https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=090000168007cf98. Accessed 20 February 2020"
    },
    {
      "key": "480_CR12",
      "unstructured": "Culver KW, Osborne WRA, Miller AD, Fleisher TA, Berger M, Anderson WF, Blaese RM (1991) Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant Proc"
    },
    {
      "key": "480_CR13",
      "unstructured": "DBGen (2019) Gene therapies open very promising scenarios for the treatment of genetic blindness. DBGen Ocular Genetics. https://dbgen.com/en/gene-therapies-open-very-promising-scenarios-for-the-treatment-genetic-blindness/. Accessed 20 February 2020"
    },
    {
      "key": "480_CR14",
      "unstructured": "Deena Beasley TM (2019) Bluebird prices gene therapy at 1.58 million euros over 5 years. REUTERS Health News. https://www.reuters.com/article/us-bluebird-bio-gene-therapy-price/bluebird-prices-gene-therapy-at-1-575-million-euros-over-five-years. Accessed 20 February 2020"
    },
    {
      "DOI": "10.1534/genetics.104.036871",
      "author": "AM Deutschbauer",
      "doi-asserted-by": "publisher",
      "first-page": "1915",
      "journal-title": "Genetics.",
      "key": "480_CR15",
      "unstructured": "Deutschbauer AM, Jaramillo DF, Proctor M, Kumm J, Hillenmeyer ME, Davis RW, Nislow C, Giaever G (2005) Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast. Genetics. 169:1915–1925. https://doi.org/10.1534/genetics.104.036871",
      "volume": "169",
      "year": "2005"
    },
    {
      "DOI": "10.3390/ijms20102542",
      "doi-asserted-by": "publisher",
      "key": "480_CR16",
      "unstructured": "Diakatou M, Manes G, Bocquet B, Meunier I, Kalatzis V (2019) Genome editing as a treatment for the most prevalent causative genes of autosomal dominant retinitis pigmentosa. Int J Mol Sci 20. https://doi.org/10.3390/ijms20102542"
    },
    {
      "DOI": "10.1038/d41587-019-00015-6",
      "author": "E Dolgin",
      "doi-asserted-by": "publisher",
      "first-page": "699",
      "journal-title": "Nat Biotechnol",
      "key": "480_CR17",
      "unstructured": "Dolgin E (2019) “Bubble boy” gene therapy reignites commercial interest. Nat Biotechnol 37:699–701. https://doi.org/10.1038/d41587-019-00015-6",
      "volume": "37",
      "year": "2019"
    },
    {
      "DOI": "10.1126/science.aan4672",
      "doi-asserted-by": "crossref",
      "key": "480_CR18",
      "unstructured": "Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M (2018) Gene therapy comes of age. Science 359(6372):eaan4672"
    },
    {
      "author": "Editas Medicine, Allergan",
      "key": "480_CR19",
      "unstructured": "Editas Medicine, Allergan (2019) Allergan and Editas Medicine initiate the brilliance phase 1/2 clinical trial of AGN-151587 (EDIT-101) for the treatment of LCA10. Editas Medicine Inc., Dublin and Cambridge Accessed 20 February 2020",
      "volume-title": "Allergan and Editas Medicine initiate the brilliance phase 1/2 clinical trial of AGN-151587 (EDIT-101) for the treatment of LCA10",
      "year": "2019"
    },
    {
      "author": "Editas Medicine, Allergan",
      "key": "480_CR20",
      "unstructured": "Editas Medicine, Allergan (2020) Allergan and Editas Medicine announce dosing of first patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10. Editas Medicine Inc., Dublin and Cambridge Accessed 5 March 2020",
      "volume-title": "Allergan and Editas Medicine announce dosing of first patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10",
      "year": "2020"
    },
    {
      "DOI": "10.1073/pnas.90.2.720",
      "author": "Z Eshhar",
      "doi-asserted-by": "publisher",
      "first-page": "720",
      "journal-title": "Proc Natl Acad Sci U S A",
      "key": "480_CR21",
      "unstructured": "Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720–724. https://doi.org/10.1073/pnas.90.2.720",
      "volume": "90",
      "year": "1993"
    },
    {
      "key": "480_CR22",
      "unstructured": "EU Clinical Trial Register (2020) www.clinicaltrialsregister.eu. Accessed February 2020"
    },
    {
      "key": "480_CR23",
      "unstructured": "European Medicines Agency (2015) Reflection paper on classification of advanced therapy medicinal products: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf. Accessed 22 February 2020"
    },
    {
      "key": "480_CR24",
      "unstructured": "European Medicines Agency (2016) Strimvelis EPAR. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/strimvelis-epar-product-information_en.pdf. Accessed 02 February 2020"
    },
    {
      "key": "480_CR25",
      "unstructured": "European Medicines Agency. (2017) Glybera EPAR. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/glybera-epar-product-information_en.pdf. Accessed 02 February 2020"
    },
    {
      "key": "480_CR26",
      "unstructured": "European Medicines Agency (2019a) Luxturna EPAR. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/luxturna-epar-product-information_en.pdf. Accessed 02 February 2020"
    },
    {
      "key": "480_CR27",
      "unstructured": "European Medicines Agency (2019b) Zynteglo EPAR. European Medicines Agency. https://www.ema.europa.eu/en/documents/overview/zynteglo-epar-medicine-overview_en.pdf. Accessed 02 February 2020"
    },
    {
      "author": "European Medicines Agency",
      "key": "480_CR28",
      "unstructured": "European Medicines Agency (2020) Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. European Medicines Agency, Amsterdam",
      "volume-title": "Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use",
      "year": "2020"
    },
    {
      "key": "480_CR29",
      "unstructured": "European Medicines Agency (n.d.) Advanced therapy classification. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/advanced-therapy-classification. Accessed 05 February 2020"
    },
    {
      "DOI": "10.1016/j.joco.2018.10.003",
      "author": "M Fantini",
      "doi-asserted-by": "publisher",
      "first-page": "102",
      "journal-title": "J Curr Ophthalmol",
      "key": "480_CR30",
      "unstructured": "Fantini M, Asanad S, Karanjia R, Sadun A (2019) Hormone replacement therapy in Leber’s hereditary optic neuropathy: accelerated visual recovery in vivo. J Curr Ophthalmol 31:102–105. https://doi.org/10.1016/j.joco.2018.10.003",
      "volume": "31",
      "year": "2019"
    },
    {
      "DOI": "10.1038/gt.2011.172",
      "author": "GJ Farrar",
      "doi-asserted-by": "publisher",
      "first-page": "137",
      "journal-title": "Gene Ther",
      "key": "480_CR31",
      "unstructured": "Farrar GJ, Millington-Ward S, Chadderton N, Humphries P, Kenna PF (2012) Gene-based therapies for dominantly inherited retinopathies. Gene Ther 19:137–144. https://doi.org/10.1038/gt.2011.172",
      "volume": "19",
      "year": "2012"
    },
    {
      "key": "480_CR32",
      "unstructured": "FDA (2017) Luxturna Approval Letter. U.S Food \u0026 Drug Administration: https://www.fda.gov/media/109487/download. Accessed 02 February 2020"
    },
    {
      "DOI": "10.1126/science.175.4025.949",
      "author": "T Friedmann",
      "doi-asserted-by": "publisher",
      "first-page": "949",
      "journal-title": "Science.",
      "key": "480_CR33",
      "unstructured": "Friedmann T, Roblin R (1972) Gene therapy for human genetic disease? Science. 175:949–955. https://doi.org/10.1126/science.175.4025.949",
      "volume": "175",
      "year": "1972"
    },
    {
      "DOI": "10.1038/s10038-018-0535-7",
      "author": "T Fukao",
      "doi-asserted-by": "publisher",
      "first-page": "65",
      "journal-title": "J Hum Genet",
      "key": "480_CR34",
      "unstructured": "Fukao T, Nakamura K (2019) Advances in inborn errors of metabolism. J Hum Genet 64:65. https://doi.org/10.1038/s10038-018-0535-7",
      "volume": "64",
      "year": "2019"
    },
    {
      "key": "480_CR35",
      "unstructured": "Gene Therapy Net (2020) http://www.genetherapynet.com/types-of-gene-therapy.html. Accessed February 2020"
    },
    {
      "DOI": "10.1093/brain/awq276",
      "author": "C Giordano",
      "doi-asserted-by": "publisher",
      "first-page": "220",
      "journal-title": "Brain.",
      "key": "480_CR36",
      "unstructured": "Giordano C, Montopoli M, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d’Amati G, Carelli V (2011) Oestrogens ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy. Brain. 134:220–234. https://doi.org/10.1093/brain/awq276",
      "volume": "134",
      "year": "2011"
    },
    {
      "DOI": "10.1093/brain/awt343",
      "author": "C Giordano",
      "doi-asserted-by": "publisher",
      "first-page": "335",
      "journal-title": "Brain.",
      "key": "480_CR37",
      "unstructured": "Giordano C, Iommarini L, Giordano L, Maresca A, Pisano A, Valentino ML, Caporali L, Liguori R, Deceglie S, Roberti M, Fanelli F, Fracasso F, Ross-Cisneros FN, D’Adamo P, Hudson G, Pyle A, Yu-Wai-Man P, Chinnery PF, Zeviani M, Salomao SR, Berezovsky A, Belfort R Jr, Ventura DF, Moraes M, Moraes Filho M, Barboni P, Sadun F, de Negri A, Sadun AA, Tancredi A, Mancini M, d’Amati G, Loguercio Polosa P, Cantatore P, Carelli V (2014) Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy. Brain. 137:335–353. https://doi.org/10.1093/brain/awt343",
      "volume": "137",
      "year": "2014"
    },
    {
      "key": "480_CR38",
      "unstructured": "Green A (2019) Biotech companies defend prices of one-off gene therapy. Financial Times Online, pp. https://www.ft.com/content/edd639fc-9755-11e9-98b9-e38c177b152f. Accessed 15 February 2020"
    },
    {
      "DOI": "10.3109/08820538.2015.1114856",
      "author": "BP Hafler",
      "doi-asserted-by": "publisher",
      "first-page": "49",
      "journal-title": "Semin Ophthalmol",
      "key": "480_CR39",
      "unstructured": "Hafler BP, Comander J, Difranco CW, Place EM, Pierce EA (2016) Course of ocular function in PRPF31 retinitis pigmentosa. Semin Ophthalmol 31:49–52. https://doi.org/10.3109/08820538.2015.1114856",
      "volume": "31",
      "year": "2016"
    },
    {
      "key": "480_CR40",
      "unstructured": "Han Dm et al. (2003) Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up. Zhonghua Yi Xue Za Zhi"
    },
    {
      "DOI": "10.1080/20016689.2017.1265293",
      "doi-asserted-by": "publisher",
      "key": "480_CR41",
      "unstructured": "Hanna E, Rémuzat C, Auquier P, Toumi M (2017) Gene therapies development: slow progress and promising prospect. J Market Access Health Policy 5. https://doi.org/10.1080/20016689.2017.1265293"
    },
    {
      "DOI": "10.1038/nbt.3290",
      "doi-asserted-by": "crossref",
      "key": "480_CR42",
      "unstructured": "Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33(9):985–989"
    },
    {
      "DOI": "10.1002/1873-3468.12707",
      "author": "KT Jensen",
      "doi-asserted-by": "publisher",
      "first-page": "1892",
      "journal-title": "FEBS Lett",
      "key": "480_CR43",
      "unstructured": "Jensen KT, Fløe L, Petersen TS, Huang J, Xu F, Bolund L, Luo Y, Lin L (2017) Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency. FEBS Lett 591:1892–1901. https://doi.org/10.1002/1873-3468.12707",
      "volume": "591",
      "year": "2017"
    },
    {
      "DOI": "10.3389/fimmu.2016.00470",
      "doi-asserted-by": "crossref",
      "key": "480_CR44",
      "unstructured": "Juric MK, Ghimire S, Ogonek J, Weissinger EM, Holler E, van Rood JJ, Oudshoorn M, Dickinson A, Greinix HT (2016) Milestones of Hematopoietic Stem Cell Transplantation – From First Human Studies to Current Developments. Front Immunol 7"
    },
    {
      "DOI": "10.1016/j.ajo.2013.05.009",
      "author": "V Kalatzis",
      "doi-asserted-by": "publisher",
      "first-page": "433",
      "journal-title": "Am J Ophthalmol",
      "key": "480_CR45",
      "unstructured": "Kalatzis V, Hamel CP, Macdonald IM (2013) Choroideremia: towards a therapy. Am J Ophthalmol 156:433–437.e3. https://doi.org/10.1016/j.ajo.2013.05.009",
      "volume": "156",
      "year": "2013"
    },
    {
      "DOI": "10.2165/11594020-000000000-00000",
      "author": "K Kamimura",
      "doi-asserted-by": "publisher",
      "first-page": "293",
      "journal-title": "Pharmaceut Med",
      "key": "480_CR46",
      "unstructured": "Kamimura K, Suda T, Zhang G, Liu D (2011) Advances in gene delivery systems. Pharmaceut Med 25:293–306. https://doi.org/10.2165/11594020-000000000-00000",
      "volume": "25",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.2003.21.13.2508",
      "doi-asserted-by": "crossref",
      "key": "480_CR47",
      "unstructured": "Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WKA (2003) Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results. J Clin Oncol 21(13):2508–2518"
    },
    {
      "DOI": "10.1016/j.ymthe.2018.03.002",
      "author": "K Laoharawee",
      "doi-asserted-by": "publisher",
      "first-page": "1127",
      "journal-title": "Mol Ther",
      "key": "480_CR48",
      "unstructured": "Laoharawee K, DeKelver RC, Podetz-Pedersen KM, Rohde M, Sproul S, Nguyen HO, Nguyen T, St. Martin SJ, Ou L, Tom S, Radeke R, Meyer KE, Holmes MC, Whitley CB, Wechsler T, McIvor RS (2018) Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol Ther 26:1127–1136. https://doi.org/10.1016/j.ymthe.2018.03.002",
      "volume": "26",
      "year": "2018"
    },
    {
      "DOI": "10.3390/diseases6020042",
      "doi-asserted-by": "publisher",
      "key": "480_CR49",
      "unstructured": "Lundstrom K (2018) Viral vectors in gene therapy. Diseases 6. https://doi.org/10.3390/diseases6020042"
    },
    {
      "DOI": "10.1056/NEJMoa0802315",
      "author": "AM Maguire",
      "doi-asserted-by": "publisher",
      "first-page": "2240",
      "journal-title": "N Engl J Med",
      "key": "480_CR50",
      "unstructured": "Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J et al (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358:2240–2248. https://doi.org/10.1056/NEJMoa0802315",
      "volume": "358",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nbt0102-70",
      "author": "J Maher",
      "doi-asserted-by": "publisher",
      "first-page": "70",
      "journal-title": "Nat Biotechnol",
      "key": "480_CR51",
      "unstructured": "Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 20:70–75. https://doi.org/10.1038/nbt0102-70",
      "volume": "20",
      "year": "2002"
    },
    {
      "DOI": "10.1097/00041327-200020030-00006",
      "author": "Y Mashima",
      "doi-asserted-by": "publisher",
      "first-page": "166",
      "journal-title": "J Neuroophthalmol",
      "key": "480_CR52",
      "unstructured": "Mashima Y, Kigasawa K, Wakakura M, Oguchi Y (2000) Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 20:166–170. https://doi.org/10.1097/00041327-200020030-00006",
      "volume": "20",
      "year": "2000"
    },
    {
      "key": "480_CR53",
      "unstructured": "Master A (2019) Kymriah vs. Yescarta. Nucleus Biologics. https://nucleusbiologics.com/resources/kymriah-vs-yescarta/. Accessed 02 February 2020"
    },
    {
      "key": "480_CR54",
      "unstructured": "MedlinePlus (n.d.) Inborn errors of metabolism. MedlinePlus Medical Encyclopedia. https://medlineplus.gov/ency/article/002438.htm. Accessed 03 February 2020"
    },
    {
      "DOI": "10.1093/hmg/ddn202",
      "author": "HF Mendes",
      "doi-asserted-by": "publisher",
      "first-page": "3043",
      "journal-title": "Hum Mol Genet",
      "key": "480_CR55",
      "unstructured": "Mendes HF, Cheetham ME (2008) Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. Hum Mol Genet 17:3043–3054. https://doi.org/10.1093/hmg/ddn202",
      "volume": "17",
      "year": "2008"
    },
    {
      "key": "480_CR56",
      "unstructured": "MeSH (2020) \"MeSH Descriptor Data: Metabolic diseases\". National Library of Medicine. https://meshb.nlm.nih.gov/record/ui?ui=D008659. Accessed 03 February 2020"
    },
    {
      "key": "480_CR57",
      "unstructured": "MIT NEWDIGS Initiative (2017) Finances of Cures in the US (FoCUS) Research brief. Massachussetes Institute of Technology. https://newdigs.mit.edu/sites/default/files/FoCUS_Research_Brief_2017F211v011.pdf. Accessed 29 May 2020."
    },
    {
      "key": "480_CR58",
      "unstructured": "Mitha F (2019) The return of Gene Therapy. Labiotech. https://www.labiotech.eu/features/gene-therapy-history/. Accessed 03 February 2020"
    },
    {
      "DOI": "10.1126/science.272.5259.263",
      "author": "L Naldini",
      "doi-asserted-by": "publisher",
      "first-page": "263",
      "journal-title": "Science.",
      "key": "480_CR59",
      "unstructured": "Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:263–267. https://doi.org/10.1126/science.272.5259.263",
      "volume": "272",
      "year": "1996"
    },
    {
      "key": "480_CR60",
      "unstructured": "National Academy of Science (2017) Human Genome Editing - Science, Ethics and governance. National Academy of Science \u0026 National Academy of Medicine"
    },
    {
      "key": "480_CR61",
      "unstructured": "National Cancer Institute (2015) What Is Cancer?. National Cancer Institute: https://www.cancer.gov/about-cancer/understanding/what-is-cancer. Accessed 03 February 2020"
    },
    {
      "key": "480_CR62",
      "unstructured": "Novartis (2020) Understanding Kymriah. Kymriah: https://www.us.kymriah.com/acute-lymphoblastic-leukemia-children/about-kymriah/understanding-kymriah/"
    },
    {
      "author": "Nuffield Council on Bioethics",
      "key": "480_CR63",
      "unstructured": "Nuffield Council on Bioethics (2018) Patient access to experimental treatment. Nuffield Council on Bioethics, London",
      "volume-title": "Patient access to experimental treatment",
      "year": "2018"
    },
    {
      "DOI": "10.1080/14712598.2018.1484448",
      "author": "MI Patrício",
      "doi-asserted-by": "publisher",
      "first-page": "807",
      "journal-title": "Expert Opin Biol Ther",
      "key": "480_CR64",
      "unstructured": "Patrício MI, Barnard AR, Xue K, MacLaren RE (2018) Choroideremia: molecular mechanisms and development of AAV gene therapy. Expert Opin Biol Ther 18:807–820. https://doi.org/10.1080/14712598.2018.1484448",
      "volume": "18",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.omtm.2018.08.003",
      "doi-asserted-by": "crossref",
      "key": "480_CR65",
      "unstructured": "Psatha N, Reik A, Phelps S, Zhou Y, Dalas D, Yannaki E, Levasseur DN, Urnov FD, Holmes MC, Papayannopoulou T (2018) Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major. Mol Ther - Methods \u0026 Clinical Development 10:313–326"
    },
    {
      "DOI": "10.1016/j.ymgme.2003.08.016",
      "author": "SE Raper",
      "doi-asserted-by": "publisher",
      "first-page": "148",
      "journal-title": "Mol Genet Metab",
      "key": "480_CR66",
      "unstructured": "Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148–158. https://doi.org/10.1016/j.ymgme.2003.08.016",
      "volume": "80",
      "year": "2003"
    },
    {
      "DOI": "10.2174/1874467210801010013",
      "doi-asserted-by": "crossref",
      "key": "480_CR67",
      "unstructured": "Raty J, Pikkarainen J, Wirth T, Yla-Herttuala S (2008) Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications. Curr Mol Pharmacol 1(1):13–23"
    },
    {
      "DOI": "10.1007/978-3-540-75276-9",
      "author": "A Rochi",
      "doi-asserted-by": "publisher",
      "key": "480_CR68",
      "unstructured": "Rochi A (2009) In: Ronchi AM (ed) eCulture: cultural content in the digital age. Springer, Berlin",
      "volume-title": "eCulture: cultural content in the digital age",
      "year": "2009"
    },
    {
      "DOI": "10.1002/emmm.201000083",
      "doi-asserted-by": "crossref",
      "key": "480_CR69",
      "unstructured": "Roselli EA, Mezzadra R, Frittoli MC, Maruggi G, Biral E, Mavilio F, Mastropietro F, Amato A, Tonon G, Refaldi C, Cappellini MD, Andreani M, Lucarelli G, Roncarolo MG, Marktel S, Ferrari G (2010) Correction of β‐thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med 2(8):315–328"
    },
    {
      "DOI": "10.1056/NEJM199008303230904",
      "author": "SA Rosenberg",
      "doi-asserted-by": "publisher",
      "first-page": "570",
      "journal-title": "N Engl J Med",
      "key": "480_CR70",
      "unstructured": "Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF (1990) Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578. https://doi.org/10.1056/NEJM199008303230904",
      "volume": "323",
      "year": "1990"
    },
    {
      "DOI": "10.1073/pnas.1718446115",
      "author": "YT Tan",
      "doi-asserted-by": "publisher",
      "first-page": "2180",
      "journal-title": "Proc Natl Acad Sci U S A",
      "key": "480_CR71",
      "unstructured": "Tan YT, Ye L, Xie F, Beyer AI, Muench MO, Wang J, Chen Z, Liu H, Chen SJ, Kan YW (2018) Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor. Proc Natl Acad Sci U S A 115:2180–2185. https://doi.org/10.1073/pnas.1718446115",
      "volume": "115",
      "year": "2018"
    },
    {
      "DOI": "10.1007/BF00464689",
      "author": "HG Terheggen",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Z Kinderheilkd",
      "key": "480_CR72",
      "unstructured": "Terheggen HG, Lowenthal A, Lavinha F, Colombo JP, Rogers S (1975) Unsuccessful trial of gene replacement in arginase deficiency. Z Kinderheilkd 119:1–3. https://doi.org/10.1007/BF00464689",
      "volume": "119",
      "year": "1975"
    },
    {
      "DOI": "10.3390/vaccines2030624",
      "author": "T Ura",
      "doi-asserted-by": "publisher",
      "first-page": "624",
      "journal-title": "Vaccines.",
      "key": "480_CR73",
      "unstructured": "Ura T, Okuda K, Shimada M (2014) Developments in viral vector-based vaccines. Vaccines. 2:624–641. https://doi.org/10.3390/vaccines2030624",
      "volume": "2",
      "year": "2014"
    },
    {
      "key": "480_CR74",
      "unstructured": "What is Genome Editing? NIH (2019) Genome.gov: https://www.genome.gov/about-genomics/policy-issues/what-is-Genome-Editing. Accessed 03 February 2020"
    },
    {
      "key": "480_CR75",
      "unstructured": "WHO (2020) Genetic research. World Health Organization: https://www.who.int/genomics/research/en/. Accessed 15 February 2020"
    },
    {
      "key": "480_CR76",
      "unstructured": "Zafar SY, Abernethy AP (2013) Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park)"
    },
    {
      "DOI": "10.3389/fimmu.2017.00533",
      "doi-asserted-by": "publisher",
      "key": "480_CR77",
      "unstructured": "Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS (2017) Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol 8. https://doi.org/10.3389/fimmu.2017.00533"
    }
  ],
  "reference-count": 77,
  "references-count": 77,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s12687-020-00480-6"
    }
  },
  "score": 0,
  "short-container-title": [
    "J Community Genet"
  ],
  "source": "Crossref",
  "title": [
    "Curative gene therapies for rare diseases"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "12"
}